Neurocrine Biosciences, Inc. (NASDAQ:NBIX) has earned a consensus rating of “Buy” from the nineteen research firms that are presently covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a hold rating and eighteen have issued a buy rating on the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $81.13.

A number of research analysts have recently commented on NBIX shares. BMO Capital Markets increased their target price on Neurocrine Biosciences from $83.00 to $109.00 and gave the company an “outperform” rating in a research report on Thursday, November 2nd. Jefferies Group reiterated a “buy” rating and set a $69.00 target price (up from $66.00) on shares of Neurocrine Biosciences in a research report on Tuesday, October 3rd. Oppenheimer set a $85.00 target price on Neurocrine Biosciences and gave the company a “buy” rating in a research report on Tuesday, December 12th. Needham & Company LLC reiterated a “buy” rating and set a $86.00 target price on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd. Finally, Leerink Swann reiterated an “outperform” rating and set a $83.00 target price (up from $72.00) on shares of Neurocrine Biosciences in a research report on Thursday, November 2nd.

In other Neurocrine Biosciences news, insider Kyle Gano sold 24,818 shares of the stock in a transaction on Thursday, November 2nd. The stock was sold at an average price of $71.05, for a total value of $1,763,318.90. Following the sale, the insider now owns 84,596 shares in the company, valued at $6,010,545.80. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Gary A. Lyons sold 10,000 shares of the stock in a transaction on Friday, December 1st. The stock was sold at an average price of $72.92, for a total value of $729,200.00. Following the completion of the sale, the director now owns 272,066 shares in the company, valued at approximately $19,839,052.72. The disclosure for this sale can be found here. Insiders have sold a total of 116,405 shares of company stock worth $8,588,519 in the last 90 days. 4.80% of the stock is currently owned by insiders.

A number of hedge funds have recently added to or reduced their stakes in NBIX. The Manufacturers Life Insurance Company increased its stake in Neurocrine Biosciences by 7.8% in the second quarter. The Manufacturers Life Insurance Company now owns 2,665 shares of the company’s stock worth $123,000 after purchasing an additional 193 shares during the period. Crow Point Partners LLC purchased a new stake in Neurocrine Biosciences in the fourth quarter worth $145,000. Stephens Inc. AR purchased a new stake in Neurocrine Biosciences in the second quarter worth $207,000. Comerica Bank purchased a new stake in Neurocrine Biosciences in the third quarter worth $210,000. Finally, Ardsley Advisory Partners purchased a new stake in Neurocrine Biosciences in the second quarter worth $230,000.

Neurocrine Biosciences (NBIX) opened at $81.37 on Monday. The company has a current ratio of 14.38, a quick ratio of 14.37 and a debt-to-equity ratio of 1.05. The company has a market capitalization of $7,200.68, a P/E ratio of -36.65 and a beta of 0.35. Neurocrine Biosciences has a 52-week low of $38.43 and a 52-week high of $83.84.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its earnings results on Wednesday, November 1st. The company reported ($0.13) EPS for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.36. The firm had revenue of $60.77 million for the quarter, compared to the consensus estimate of $29.38 million. During the same quarter in the prior year, the company posted ($0.43) earnings per share. sell-side analysts predict that Neurocrine Biosciences will post -1.61 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This piece was reported by American Banking News and is owned by of American Banking News. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international trademark & copyright laws. The legal version of this piece can be viewed at https://www.americanbankingnews.com/2018/01/15/neurocrine-biosciences-inc-nbix-given-average-rating-of-buy-by-analysts.html.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Analyst Recommendations for Neurocrine Biosciences (NASDAQ:NBIX)

Receive News & Ratings for Neurocrine Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurocrine Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.